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Abstract
Background: Human neuroblastoma (NB) cell lines may present with either one of the so-called S-and N-subtypes.
We have previously reported a strong correlation between protein expression levels of vimentin, an S-subtype
marker, and the p21Waf1 cyclin-dependent kinase inhibitor. We here investigated whether this correlation extend to
the mRNA level in NB cell lines as well as in patients’ tumors. We also further explored the relationship between
expression of vimentin and p21, by asking whether vimentin could regulate p21 expression.
Methods: Vimentin and p21 mRNA levels in NB cell lines as well as in patients’ tumors (n = 77) were quantified
using Q-PCR. Q-PCR data obtained from tumors of high risk NB patients (n = 40) were analyzed in relation with the
overall survival using the Log-rank Kaplan-Meier estimation. siRNA-mediated depletion or overexpression of
vimentin in highly or low expressing vimentin cell lines, respectively, followed by protein expression and promoter
activation assays were used to assess the role of vimentin in modulating p21 expression.
Results: We extend the significant correlation between vimentin and p21 expression to the mRNA level in NB cell
lines as well as in patients’ tumors. Overall survival analysis from Q-PCR data obtained from tumors of high risk
patients suggests that lower levels of p21 expression could be associated with a poorer outcome. Our data
additionally indicate that the correlation observed between p21 and vimentin expression levels results from p21
transcriptional activity being regulated by vimentin. Indeed, downregulating vimentin resulted in a significant
decrease in p21 mRNA and protein expression as well as in p21 promoter activity. Conversely, overexpressing
vimentin triggered an increase in p21 promoter activity in cells with a nuclear expression of vimentin.
Conclusion: Our results suggest that p21 mRNA tumor expression level could represent a refined prognostic factor
for high risk NB patients. Our data also show that vimentin regulates p21 transcription; this is the first
demonstration of a gene regulating function for this type III-intermediate filament.
Background
Neuroblastoma (NB), the most common extracranial
solid tumor in children, derives from the sympathetic
nervous system. It may follow various courses, from
spontaneous regression (stage 4S) to aggressive treat-
ment-resistant diseases, which is often metastatic (stage
4) when diagnosed in children aged 12 months or older.
This refractory form predominates over all other forms
of NB and has a poor prognosis, with an event-free sur-
vival at five years of only 30% [1,2].
NB tumors display various morphologies [1] and NB-
derived cell lines are classified into two subtypes on the
basis of their appearance and expression profiles, the
“N” (Neuronal) and “S” (Substrate-adherent) types [3].
N-type NB cells produce neurofilament proteins and
neuron-specific enolase (NSE) but little or no vimentin.
Conversely, S-type NB cells produce larger amounts of
vimentin than N-type cells [3]. We have previously
reported the existence of distinctly altered cellular
responses to DNA double-strand breaks (DSB) in “N-
type” versus “S-type” NB cell lines [4]. In the course of
this work, we also noticed that the expression of the
type-III intermediate filament vimentin, a marker of S-
type cells, correlated with that of the p21Waf1 cyclin-
dependent kinase (CDK) inhibitor [4]. Several lines of
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data support the involvement of vimentin in the regula-
tion of gene expression and in the maintenance of gen-
ome stability [5]. Indeed, vimentin, which is known to
interact with DNA directly via its N-terminal non-heli-
cal domain [6], binds mobile and repetitive sequence
elements as well as nuclear matrix attachment regions
(MARs) and also displays a strong affinity for four-way
junctions [7,8].
We have now verified that the previously reported cor-
relation between expression of vimentin and p21 also
existed at the mRNA level in NB cell lines. This allowed
us to extend our analysis to tumor samples in which p21
mRNA levels were found associated with clinical evolu-
tion. We also report that vimentin partly localizes to the
nucleus of NB cells and regulates p21 transcription.
Methods
Cell culture, transfections and chemical treatments
Ten NB cell lines derived from patients with advanced
stages of disease were used: SK-N-SH, CHP-212, GI-M-
EN, CLB-Pe, LAN-5, SJN-B1, CLB-Ga, IGR-N-91, Kelly
and IMR32. They were cultured as described [4].
For siRNA transient transfections, cells were either left
untreated (Unt.) or submitted to 2 successive transfec-
tions at 4 days interval with either siRNA (siCTRL or
siVIM, see below) at a 100 nM concentration with
Dharmafect 1 (Dharmacon) according to manufacturer’s
instructions. Four days after the second transfection,
cells were treated for 30 min with 200 ng/ml of neocar-
zinostatin (NCS, Sigma) to induce an ATM-dependent
response to DNA double-strand breaks or left untreated.
In luciferase assays, cells were transfected with 800 ng
of pGL3-luc negative control or pWaf1-luc using the
Lipofectamine LTX reagent (Invitrogen), according to
manufacturer’s instructions.
For overexpression assays, cells were transfected with
1.5 μg of pcDNA3.1 (CTRL) or pcDNA3.1-VIM using
Lipofectamine LTX (Invitrogen). For luciferase assays,
they were concomitantly transfected with either 500 ng
of pGL3-luc or pWaf1-luc.
For the establishment of stable clones, SK-N-SK cells
seeded in 10 cm dishes were transfected with 24 μg of
the shRNA-VIM containing vector with Lipofectamine
2000 (Invitrogen). Clones were selected under 1 μg/ml
puromycin for 14 days.
Tumor samples
Ethics approval of the study was obtained from the
French Neuroblastome Review Board (chairman Dr
Herbé Rubie, Toulouse, France “rubie.h@chu-toulouse.
fr”). According to the form of the neuroblastoma disease
and patient age at diagnosis (localized or metastatic), as
well as MYCN content, specific National protocols are
systematically applied in each referenced french center.
Tumor material from NB patients (n = 77) (Additional
file 1, Table S1) was obtained at diagnosis at the Institut
Gustave Roussy (french center that is referenced for
neuroblastoma therapeutic management) with written
parents’ informed consent. Indeed, in each french center
that is referenced for neuroblastoma therapeutic man-
agement, before diagnosis statement, parents are
informed (written information of pediatric oncologist at
the end of 1st consultation), and they are asked for a
signed consent of authorizations regarding computeriza-
tion of data (parents authorization with regards to com-
puterization of data) as well as use of remainders of
tumor tissues (parents’ authorization with regards to use
of tumor tissues that remains from the systematic
MYCN genome content test for improvement of diagno-
sis and therapy).
According to the International Neuroblastoma Staging
System (INSS), patients were staged as follows: Stage 4
S (n = 11), Stage 1 (n = 6), Stage 2 (n = 10), Stage 3 (n
= 4) and Stage 4 (n = 47, with 6 < 12 months). Total
RNAs were extracted and corresponding cDNA
obtained as described [9].
Real-time quantitative PCR analysis
Total mRNA from exponential growing culture of high
risk NB cell lines or NB tumor samples were extracted
with the RNeasy Mini Kit and the RNeasy Micro Kit
(Qiagen). After quantification with a NanoDrop 1000
(Labtech), 1 μg of cell lines mRNA or 200 ng of tumor
samples mRNA were converted in cDNA as described
previously [4]. Vimentin and p21 mRNA quantification
was assessed by Q-PCR with an AbiPrism 7900HT appa-
ratus (Applied Biosystems), in a 25 μl reaction volume
containing 12.5 ng of cDNA template, 10 pmol of each
primers, and 12.5 μl of Sybr Green Master Mix (Applied
Biosystems), with the following oligonucleotides. For
vimentin: Vim_F: 5′- AAGAGAACTTTGCCGTTGAA-3′
and Vim_R: 5′-GTGATGCTGAGAAGTTTCGT-3′. For
p21: p21_F: 5′-GGATGTCCGTCAGAACCCAT-3′ and
p21_R: 5′- CCCTCCAGTGGTGTCTCGGTG-3′. Nor-
malization was assessed after quantification of GAPDH
mRNA or 18 S rRNA levels as indicated with the follow-
ing oligonucleotides: GAPDH_F: 5′-CTGCACCAC-
CAACTGCTTAG-3′ and GAPDH_R: 5′-AGGTCCAC
CACTGACACGTT-3′; 18S_F: 5′- cggctaccacatccaaggaa-
3′ and 18S_R: 5′- GCTGGAATTACCCCGGCT-3′.
siRNAs and constructs
RNA interference experiments were performed using
“siVIM” (siGENOME SMART pool for human vimentin,
Dharmacon), “siCTRL” (ON-TARGETplus siCONTROL
Non-targeting pool, Dharmacon), or the pLKO.1 vector
containing the vimentin-targeting shRNA (MISSION
shRNA TRCN0000029123, Sigma). The plasmid
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construct pcDNA3.1-VIM was obtained by cloning the
full-length vimentin cDNA (KpnI-Not1) from the
pCMV-SPORT6-VIM vector (clone 2985712, Accession
Number: BC000163, OpenBiosystems) in the pcDNA3.1
vector (Invitrogen). The pWaf1-luc reported plasmid
was kindly provided by Dr May [10]. The pcDNA3.1
(Invitrogen) and pGL3-luc vectors (Promega) were used
as negative controls.
Western Blot analysis
Total cellular extracts or differential fractionation into
cytoplasmic and nuclear extracts were performed and
submitted to SDS-PAGE as described previously [4].
The primary antibodies used were all monoclonal anti-
bodies and were: anti-vimentin RV202 (1:1000 dilution;
Abcam), anti-p21 (F-5; 1:200 dilution; Santa Cruz Bio-
technology), anti-a-Tubulin (1:1000 dilution, Sigma),
anti-b-actin (1:5000 dilution; Chemicon International
Inc.), anti-Topoisomerase IIa (ab45175, 1:20000 dilu-
tion; Abcam).
Immunofluorescence analysis
Cells were seeded on coverslips placed in a 6-wells plate
and incubated overnight. Cells were then washed once
with PBS, fixed with 4% paraformaldehyde in PBS for 30
min, and rinsed 3 times with PBS. Incubation with cold
methanol for 5 min at -20°C was used to permeabilize
the cells. Cells were then washed 3 times with PBS and
non-specific binding sites were blocked by incubation
with PBS-FCS 10% for 30 min. Cells were subsequently
incubated with either PBS-BSA 0.1% without any pri-
mary antibody, with the mouse anti-Vim antibody
RV202 (Figure S2) or with a mix of the goat anti-Vim
antibody (1:20 dilution; Sigma) and the mouse anti-
Lamin A/C antibody (clone 636; 1:50 dilution; Santa
Cruz Biotechnology) (Figure S3). Cells were rinsed 3
times with PBS, and incubated with PBS-BSA 0.1% con-
taining the secondary antibodies at a 1:400 dilution
(Alexa 488-conjugated donkey anti-goat, Alexa 647-con-
jugated chicken anti-mouse, Invitrogen) and cells were
then washed 3 times in PBS. Images were taken from a
63X immersion objective of a LSM-510 microscope
(Zeiss). z-stacked focal planes presented in the figures
are those with the denser/darker DAPI staining, thus
corresponding to the inside of nuclei.
Luciferase reporter assays
For luciferase reporter assays, cells were lysed with Pas-
sive Lysis Buffer (50 μl/well) provided with the Lucifer-
ase Reporter Assay System (Promega) 24 h after
reporter plasmids transfection. Firefly luciferase activity
was measured in duplicate with the Luciferase Reporter
Assay System (Promega), and luminosity was measured
with the Microlumat LB96P apparatus (Berthold EG &
G Instrument). The luciferase activity measured after
transfection of the pGL3-luc negative control vector was
equal to the background in each cell line (not reported).
Statistical analysis
The Mann-Whitney (luciferase assays) and log-rank sta-
tistical tests (overall survival analysis) were performed
with the Graph Pad Prism Software version 4.0. The
p value cut-off for significance is 0.05.
Results and Discussion
Expression levels of vimentin and p21 correlate in NB cell
lines and tumor samples with low p21 expression being
associated with worse prognosis in high risk patients
We initially observed that levels of vimentin and p21
were correlated at the protein level in S-type-like NB
cell lines [4]. To test whether this was also true at the
mRNA level, ten NB cell lines were tested by real-time
quantitative PCR (Q-PCR). As seen in Figure 1A, the
three S-type-like cell lines expressed high levels of
vimentin and p21 mRNAs. Although more heteroge-
neous, expression levels were consistently lower in the
six N-type-like cell lines tested.
We then measured mRNA levels for both vimentin
and p21 in NB tumor samples obtained at diagnosis
from 77 children (all stages; see Additional file 1: Table
S1). We found a highly significant correlation between
the mRNA levels of the two genes (Spearman r =
0.5787, 95% confidence interval (CI) = 0.4019 to 0.7139,
p < 0.0001) (Figure 1B). Although weaker, this correla-
tion held true when the 40 stage 4 NB tumor samples
were considered separately (Spearman r = 0.3719, 95%
CI = 0.0587 to 0.6184, p = 0.0181) (Figure 1C, left
panel). We thus conclude that vimentin and p21 mRNA
levels are correlated in both NB cell lines and tumor
samples.
Loss of p21 expression has been reported to be a poor
prognostic factor in colorectal carcinomas and small-cell
lung cancers [11]. In the presently used NB cohort, no
statistically significant association was identified between
p21 mRNA levels in tumor cells and any available clini-
cal data (age at diagnosis, INSS stage, MYCN amplifica-
tion status) (data not shown). Many reports have
indicated that clinical and genomic tumor criteria allow
a prognostic classification of NB [12,13]. However, no
stratifying prognostic factor has been proposed so far
for high risk NB (MYCN-amplified and stage 4 NB of
patients > 12 months). We here analyzed p21 tumor
expression levels in relation with the overall survival
(OS) of the 40 high risk NB patients. Despite the limited
size of the cohort, two groups of patients were identified
using the Log-rank Kaplan-Meier estimation (Figure 1C,
right panel) that appeared to exhibit different survival
curves according to the “high” or “low” p21 mRNA
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Figure 1 Vimentin-p21 mRNA correlation in NB cell lines and tumors - Association between p21 expression and clinical evolution. A.
mRNA quantification of vimentin (left panel) and p21 (right panel) relative expression level after GAPDH normalization, in 10 high risk NB cell
lines, using Sybr Green Q-PCR. The S- or N-subtype of the NB cell lines is indicated. This result was confirmed after EF1a normalization and by
TaqMan Q-PCR quantification, using two different genes for normalization (18 S and TFRC) (data not shown). Bars and error bars represent the
means and standard deviations, respectively. B. Representation of the p21 mRNA relative expression level according to that of vimentin,
quantified by Sybr Green Q-PCR after 18 S normalization, in 77 NB tumor samples collected at the time of diagnosis (primary tumor biopsies or
metastatic bone marrows, all containing more than 70% of tumor cells) (Clinical data are presented in Additional file 1, Table S1). A cDNA
sample from the SK-N-SH cell line was used as a reference to integrate all the data together in a unique analysis. The Spearman statistical test
was performed with the Graph Pad Prism Software version 4.0. CI: Confidence Interval. C. Left panel: Representation of the p21 mRNA relative
expression level according to that of vimentin, quantified by TaqMan Q-PCR after 18 S normalization, in the 40 high risk NB tumor samples of
the cohort. The Spearman statistical test was performed as in 1B. This result was obtained using either Sybr-Green or TaqMan technology with
two normalization genes, 18 S and GAPDH, or 18 S and TFRC, respectively (data not shown). Right panel: The survival analysis of patients older
than one year of age with a stage 4 NB (N = 40) was performed using the Log-rank Kaplan-Meier estimation with the Graph Pad Prism Software
version 4.0. The overall survival was defined as the time in months between diagnosis and death or last follow-up (excluding patients who died
from toxicity). Patients were separated into two distinct groups according to their p21 mRNA tumor relative expression level quantified by Q-PCR
as in the left panel. The median of p21 tumor expression was chosen as a cut-off between high (> median, black line) and low (< median, grey
line) expression. HR: Hazard Ratio, CI: Confidence Interval.
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expression levels in the corresponding tumors (p =
0.2141, Hazard Ratio (HR) = 1.598, 95% CI = 0.7610 to
3.384), the median tumor p21 mRNA level of the cohort
being chosen as the cut-off between high (> median)
and low (< median) levels of expression. The patients
with low p21 tumor expression at diagnosis had a 24.6
months median survival compared with 37.2 in high p21
tumor expressors.
We analyzed the relationship between p21 mRNA
expression in stage 4 NB tumors and overall survival
using microarray gene expression data from the R2
repository http://hgserver1.amc.nl/cgi-bin/r2/main.cgi.
While the p21 probe set #202284 did not give significant
results, the p21 probe set #1555186 revealed that low
levels of p21 mRNA are highly significantly associated
with a reduced OS (data not shown), consistent with the
tendency we observed.
Altogether, these results suggest that our finding
would be of great interest to orientate therapeutic deci-
sions, if confirmed in larger groups of high risk NB
patients.
Vimentin participates in p21 transcriptional regulation
To further explore the relationship between expression
of vimentin and p21, we then asked whether vimentin
could regulate p21 expression. A pool of siRNAs was
used to inhibit vimentin expression in the SK-N-SH S-
type-like NB cell line (Figure 2A). First of all, it is worth
noting that vimentin depletion was not accompanied by
any cellular morphological changes (data not shown).
Q-PCR analysis (upper panel) revealed that p21 and
vimentin mRNA levels decreased concomitantly.
Whereas p21 was strongly induced in vimentin expres-
sing control cells whose DNA was damaged following
NCS treatment, cells inhibited for vimentin expression
using siRNAs proved unresponsive to NCS with hardly
any increase in p21 expression (lower panel). We also
generated SK-N-SH clones stably expressing a shRNA
directed against a vimentin mRNA sequence different
from that targeted by the siRNAs. Four SK-N-SH
shRNA-Vim clones were selected with various protein
expression levels of vimentin. Strikingly, p21 protein
levels were found to strictly correlate with those of
vimentin (r = 0.97, see Additional file 2, Figure S1).
Altogether, these results suggest that vimentin may
directly or indirectly regulate p21 expression.
As vimentin has been reported to bind nucleic acids
[7,14], we then used confocal immunofluorescence
microscopy to determine the cellular distribution of
vimentin in NB cell lines. The two cell lines strongly
expressing vimentin, SK-N-SH and GI-M-EN, displayed
much stronger staining than the SJN-B1 and Kelly cell
lines, which produce little or no vimentin, respectively
(see Additional file 2, Figure S2). In addition to the clas-
sical dense cytoplasmic staining for filamentous vimen-
tin, we observed weak but nonetheless evident staining
for vimentin in the nucleus of SK-N-SH and GI-M-EN
cells (see Additional file 2, Figure S2). We also observed
some interesting colocalization of vimentin with the
nuclear matrix lamin A/C protein on the inner side of
the nuclear membrane (see Additional file 3, Figure S3).
We then used a biochemical approach for the detection
of nuclear and cytoplasmic soluble proteins by immuno-
blotting. Soluble vimentin was detected in nuclear
extracts in all three cell lines strongly expressing vimen-
tin (SK-N-SH, CHP-212, GI-M-EN), and, to a lower
extent, in the SJN-B1 cell line, which contained smaller
amounts of vimentin, but no soluble vimentin was
detected in the nucleus of the vimentin-negative Kelly
cell line (Figure 2B). However, we cannot formally
exclude the potential binding of vimentin to the outside
of the nucleus that could produce its inclusion in the
nuclear fraction.
Being potentially partly localized in the nucleus,
vimentin may well behave like a bona fide transcription
factor in these NB cells. To test this hypothesis, the SK-
N-SH, CHP-212 or GI-M-EN cell lines which express
high levels of p21 were transfected with plasmid vectors
containing the luciferase reporter gene downstream
from either 2400 bp of the p21 gene promoter (pWaf1-
luc; [10]) or a minimal gene promoter used as a control
(pGL3-luc). In all three cell lines, p21 promoter activity
depended upon the expression of vimentin as demon-
strated using a vimentin siRNAs pool in comparison
with control siRNAs (Figure 2C, upper panel). Conver-
sely, co-transfecting the luciferase reporter vectors along
with a plasmid directing vimentin expression demon-
strated that the transient overexpression of vimentin
induced a significant, but moderate, increase in p21 pro-
moter activity in vimentin-negative or low-expressing
cell lines Kelly and SJN-B1, respectively. The inducing
effect was even stronger in the already high vimentin-
expressing cell line SK-N-SH (Figure 2C, lower panel).
Transfection efficiency was similar (approximately 35%
of cells transfected, data not shown) in all three cell
lines as revealed by flow cytometry analysis of cells co-
transfected with a GFP expression vector and the
pcDNA3.1-VIM plasmid. That vimentin was indeed
overexpressed in all three cell lines, albeit to different
extents, was demonstrated by immunoblotting analysis
shown in Figure 2D (upper panel). Finally, the vimentin
negative Kelly cell line and the SK-N-SH cell line which
displayed high levels of vimentin were transiently trans-
fected with an empty vector or with a construct encod-
ing vimentin. We then fractionated the cells into
cytoplasmic soluble, nuclear soluble and cytoskeletal/
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Figure 2 Vimentin participates in p21 transcriptional regulation. A. Vimentin or p21 gene expression was monitored by Q-PCR analysis
(upper panel), as described in Figure 1A. Vimentin or p21 protein levels in total cellular extracts were assessed by immunoblotting, a-Tubulin
being used as loading control (lower panel). Cells were left untransfected (Unt.) or were transfected with the siRNAs targeting vimentin (siVIM) or
control siRNA (siCTRL). Cells were either untreated (-) or NCS-treated (+). This figure is representative of 3 independent experiments. NCS:
neocarzinostatin. B. Subcellular localization of soluble vimentin assessed by differential fractionation (C, Cytoplasmic; N, nuclear) followed by
Western blot analysis in SK-N-SH, CHP-212, GI-MEN, SJN-B1 and Kelly cells lines. Topoisomerase IIa and a-Tubulin are used as controls for the
nuclear and cytoplasmic soluble fractions, respectively. C. Analysis of p21 promoter activity using luciferase assay in indicated S- or N-type-like NB
cell lines, either downregulated (siVIM) or not (siCTRL) for vimentin expression (upper panel), or overexpressing (pcDNA3.1-VIM) or not (CTRL:
pcDNA3.1) vimentin (lower panel). Comparisons were assessed with the Mann-Whitney statistical test (* and *** stand for p < 0.05 and p < 0.005
respectively). The graph is representative of 3 independent experiments. D. Upper panel: Western Blot analysis of vimentin expression in indicated
cells transiently transfected with pcDNA3.1-VIM or the empty vector (pcDNA3.1). b-actin is used as loading control. Lower panel: Vimentin cellular
distribution (C, Cytoplasmic soluble; N, nuclear soluble; Ins., Insoluble cytoskeletal/matrix-associated fractions) in vimentin overexpressing cells,
assessed by differential cellular fractionation followed by Western Blot analysis. Topoisomerase IIa and a-Tubulin are used as controls for the
nuclear and cytoplasmic soluble fractions, respectively.
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matrix-associated insoluble fractions. In all cases where
vimentin was expressed (at the basal level or after trans-
fection), most of it was detected in the insoluble frac-
tion, as expected for the cytoplasmic intermediate
filament form of the protein (Figure 2D, lower panel),
but some vimentin was also detected in the nuclear
soluble fraction.
From our results, we conclude that vimentin regulates
p21 gene transcription, directly or indirectly, through
promoter activation. Indeed, it remains unclear whether
vimentin regulates p21 gene transcription through
direct or indirect effects on its promoter, and further
experiments are required to address this issue. Vimentin
could have an indirect effect by modifying the chroma-
tin organization of the promoter, as suggested by its
specific binding to chromatin-modifying proteins, such
as the HBO1 histone acetyltransferase or the SETDB1
histone methyltransferase, by acting as transcription
cofactor, as suggested by its binding to the PIASg tran-
scription regulator [15], or by modifying the global
organization of the nucleus, as we observed colocaliza-
tion with the lamin A/C proteins known to regulate
nuclear organization [16].
Cytoskeletal proteins thus appear to be endowed with
dual functions, both in maintaining cell architecture and
in regulating gene expression. Actin has been known for
some years to regulate transcription [17]. More recently,
some lamins have been reported to perform similar
function [18] but to our knowledge, there has been no
previous demonstration of a gene regulating function
for vimentin.
In the context of neuroblastoma oncogenesis, the
expression of the vimentin and p21 genes is regulated
during neuronal differentiation. The vimentin gene is
expressed early in neural crest cells development [19]
and is involved in initiating neurite outgrowth [20,21],
and p21 is also known to be induced during neural
development [22]. Strong vimentin and p21 expression
in some tumors may indicate that oncogenesis occurred
at a specific time point in neural crest cell development.
Low or no vimentin and p21 in other tumors may indi-
cate that oncogenesis took place at a different stage of
differentiation of the tumor progenitors.
Conclusion
Here, we show a significant correlation between expres-
sion of vimentin and p21 at the mRNA level in NB cell
lines and patients’ tumors. Overall survival analysis
based on tumors of high risk patients suggest that lower
levels of p21 expression could be associated with a
poorer outcome. We additionally report that vimentin
partly localizes to the nucleus of NB cells and regulates
p21 transcription.
Additional material
Additional file 1: Table S1. Available clinical data for the n = 77 NB
patients of the studied cohort (INSS Stage, sex and age of the patient,
MYCN amplification status, patient status and follow-up). M: male, F:
female, NA: MYCN non-amplified, A: MYCN amplified, A: alive, D:
deceased.
Additional file 2: Figure S1 and Figure S2. Figure S1: Vimentin and
p21 protein expression levels assessed by immunoblotting in four SK-N-
SH clones selected for the stable expression of a construct expressing a
shRNA specific for vimentin. Figure S2: Immunofluorescence staining of
vimentin in the SK-N-SH, CHP-212, GI-M-EN, SJN-B1 and Kelly cell lines,
analyzed by confocal microscopy. Red: Vimentin; Blue: DAPI.
Additional file 3: Figure S3. Immunofluorescence staining of vimentin
and lamin A/C proteins, in the GI-M-EN, SK-N-SH and CHP-212 cell lines,
analyzed by confocal microscopy. Red: Vimentin; Green: Lamin A/C.
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